Unlocking the future: Mitochondrial genes and neural networks in predicting ovarian cancer prognosis and immunotherapy response

Table 1 Clinical features of patients in this study

	Discovery cohort	Validation cohort	Statistical method	P value
Prognostic model
	(n = 262)	(n = 113)
Survival time in days			Wilcoxon	0.5446
Median (IQR)	1012 (547, 1712)	1032 (394, 1562)
Alive			χ2 test	0.5337
Yes	104 (39.69)	41 (36.28)
No	158 (60.31)	72 (63.72)
Immunotherapy efficacy model
	(n = 18)	(n = 8)
Sensitivity to immunotherapy			Fisher’s exact	0.3945
Yes	9 (50.00)	2 (25.00)
No	9 (50.00)	6 (75.00)

Data are n (%), unless otherwise indicated. Sensitivity to immunotherapy means patients showed partial response or complete response after the use of immune checkpoint inhibitors according to response evaluation criteria in solid tumors 1.1. IQR: Interquartile range.